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http://dx.doi.org/10.1016/j.jacl.2017.0BACKGROUND: Nonadherence to cardiovascular medications, including daily, oral statin therapy,
negatively impacts outcomes in patients requiring low-density lipoprotein cholesterol (LDL-C)-
lowering therapy. The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab also reduces
LDL-C, but has a different mode of administration (subcutaneous injection).
OBJECTIVE: The objective of the study was to assess long-term adherence to alirocumab 75 or
150 mg, given every 2 weeks, in phase III trials of patients with sub-optimally controlled hypercholes-
terolemia.
METHODS: Data were pooled from 6 ODYSSEY trials (n 5 4212) with double-blind treatment
durations of 52 to 104 weeks. Adherence was reported as percentage of days receiving injections
according to dosing schedule and categorized into 100% adherence, below-planned dosing, above-
planned dosing, and both below- and above-planned dosing. Overall adherence was calculated as
100 2 (percentage of days with below-planned dosing 1 percentage of days with above-planned
dosing). Safety of alirocumab and effect on LDL-C levels were also evaluated.
RESULTS: Adherence was analyzed for 4197 patients (n 5 2786 alirocumab; n 5 1411 control).
Mean overall adherence was high (alirocumab 98.0%; control 97.8%). Among patients receiving
alirocumab, 45.7% were 100% adherent, 20.4% had below-planned dosing, 2.9% had above-planned
dosing, and 31.1% had both below- and above-planned dosing. Mean percentage reduction in LDL-Cd Regeneron Pharmaceuticals, Inc.
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Farnier et al Adherence to alirocumab in clinical trials 987(baseline to Week 52) was 45.8% to 61.9%, depending on alirocumab dose, and was comparable across
adherence categories. Treatment-emergent adverse events leading to alirocumab discontinuation were
infrequent and included myalgia and injection-site reactions (,1% each).
CONCLUSIONS: Alirocumab injections were associated with a high level of adherence over $1 year.
Infrequent below- or above-planned dosing had minimal impact on LDL-C reductions.
 2017 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Statin-based treatment constitutes the standard first-line
therapy for reducing low-density lipoprotein cholesterol
(LDL-C) levels and mitigating the risk of atherosclerotic
cardiovascular (CV) events.1,2 However, despite statin
treatment, a large proportion of patients do not achieve suf-
ficient reduction in LDL-C levels. A number of these pa-
tients may be at high CV risk, such as patients with a
history of myocardial infarction or stroke, have very high
baseline LDL-C levels, such as patients with heterozygous
familial hypercholesterolemia (HeFH), or have statin intol-
erance.3–5 Nonadherence to statin therapy is also relatively
common, particularly in real-world settings where,
compared with clinical trials, patients may be followed
less rigorously.2,6–11 In clinical trials, adherence to statins
has been reported to be 79% to 90% at 1 year and 78%
at 4 years.12,13 In contrast, in a cohort study conducted us-
ing 4 separate population-based administrative data sour-
ces, 2-year adherence rates with statin therapy were only
40.1% in patients with acute coronary syndromes, 36.1%
in patients with coronary artery disease, and 25.4% in the
primary prevention setting.8 A separate retrospective cohort
study of 229,918 patients reported that the proportion of
days covered with statin therapy was 45% in primary pre-
vention groups and 59% in secondary-prevention groups;
in both groups, adherence reduced over time, with $75%
of patients discontinuing statin therapy by 2 years from
the index date.7 A meta-analysis of CV therapy adherence
data from 20 studies demonstrated overall adherence rates
to CV therapies of 57% after a median of 24 months.10
Adherence to statin therapy was 57% and 76% in the pri-
mary and secondary prevention settings, respectively.10
Nonadherence has an adverse effect on patient outcomes
and is associated with increased healthcare costs,
morbidity, hospital readmissions, and mortality.2,14
Alirocumab (Praluent; Sanofi, and Regeneron Pharma-
ceuticals, Inc) is a fully human monoclonal antibody that
binds to and inhibits proprotein convertase subtilisin/kexin
type 9 (PCSK9), preventing degradation of LDL receptors.
This increases the number of LDL receptors on hepatocytes
and promotes the removal of LDL-C from the circulation,
thus lowering LDL-C levels.15,16 Clinical trials of
alirocumab, as a monotherapy or in combination with sta-
tins (with or without other lipid-lowering therapies[LLTs]), have demonstrated reductions in LDL-C of up to
61%.17–19 Alirocumab received Food and Drug Administra-
tion approval in the United States in July 2015 as an adjunct
to diet and maximally tolerated statin therapy for the treat-
ment of adults with HeFH or clinical atherosclerotic CV dis-
ease (CVD) who require additional LDL-C lowering.20 It
was also approved in Europe in September 2015 for use in
adults with primary hypercholesterolemia or mixed dyslipi-
demia, as an adjunct to diet either in combination with maxi-
mally tolerated statin with or without other LLTs for those
unable to reach LDL-C goals, or as a monotherapy with or
without other LLTs for those who are statin intolerant or
for whom a statin is contraindicated.21
Alirocumab is administered on a bi-weekly (Q2W)
dosing schedule by subcutaneous injections using a pre-
filled pen or syringe for self-injection.20,21 However, many
patients requiring LLT may not be experienced with
self-injected medication as, until recently, the only inject-
able LLT available was mipomersen (Kynamro; Kastle
Therapeutics), an antisense oligonucleotide targeting apoli-
poprotein B, licensed in the United States for the treatment
of homozygous familial hypercholesterolemia (HoFH),22 a
rare condition that affects approximately 1 in 300,000 indi-
viduals.23 Now, however, there are 2 injectable anti-PCSK9
monoclonal antibodies available; in addition to alirocumab,
evolocumab (Repatha; Amgen) was approved by the Food
and Drug Administration in 2015 as an adjunct to diet
and maximally tolerated statins in patients with HeFH or
atherosclerotic CVD who require additional LDL-C-
lowering or in addition to other LLTs in patients with
HoFH who require further LDL-C reduction.9,24 Similarly,
evolocumab is also approved in Europe for treating patients
with primary hypercholesterolemia or mixed dyslipidemia
unable to reach LDL-C goals with the maximum tolerated
dose of a statin or alone or in combination with other LLTs
in patients who are statin intolerant, and in patients with
HoFH in combination with other LLTs.25 Because self-
injectable PCSK9 inhibitors such as alirocumab are a new
concept in patients with hypercholesterolemia, there is a
possibility for potential concerns with regard to patient
adherence impacting on treatment outcomes.26 In a study
of patient and physician perspectives on the use of
alirocumab, both physicians and patients responded
positively to use of an injectable device, suggesting that
alirocumab treatment by either prefilled pen or syringe
988 Journal of Clinical Lipidology, Vol 11, No 4, August 2017would not deter its use in patients requiring additional
LLT.27 However, long-term adherence to self-injected alir-
ocumab has not been rigorously assessed.
In this analysis, data from 6 studies within the ODYSSEY
Phase III program were used to explore treatment adherence
to alirocumab over a period of at least 1 year.Methods
Studies and patients
Adherence to alirocumab injections was evaluated over a
period of 1 to 2 years using pooled data from 6 Phase III,
randomized, double-blind, controlled ODYSSEY trials (FH I
[NCT01623115], FH II [NCT01709500], HIGH FH
[NCT01617655], COMBO I [NCT01644175], COMBO II
[NCT01644188], and LONG TERM [NCT01507831];
Fig. 1). Study designs and results of the individual trials
have been reported previously.17,19,28–31 In short, FH I,
FH II, and HIGH FH evaluated alirocumab in patients with
HeFH,28,29 whereas COMBO I and COMBO II investigatedFigure 1 ODYSSEY Phase III studies and patient populations included i
identifiers: NCT01507831 (LONG TERM); NCT01617655 (HIGH FH
(COMBO I); NCT01644188 (COMBO II). †Alirocumab dose could be in
on Week 8 LDL-C level. n: randomized and treated patients. CV, cardiovasc
hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; LLT, lialirocumab in patients with high CV risk.19,30 LONG TERM
assessed alirocumab in patients with HeFH or those at high
CV risk.17 With the exception of COMBO II, which included
ezetimibe as an active comparator, all trials were placebo-
controlled. Patients were followed for at least 52 weeks
(COMBO I: 52 weeks; COMBO II: 104 weeks; all other
studies: 78 weeks; Fig. 1).
All 6 trials enrolled patients with sub-optimally
controlled hypercholesterolemia who had been receiving
maximally tolerated, potent statin therapy for at least
4 weeks before study entry. The use of nonstatin LLTs
was permitted in all studies except COMBO II. FH I, FH II,
COMBO I, and COMBO II included patients who had
baseline LDL-C levels $70 mg/dL (1.8 mmol/L) and
established CVD, or those with LDL-C $100 mg/dL
(2.59 mmol/L) at baseline without a history of documented
CVD or coronary heart disease risk equivalents. HIGH FH
enrolled patients with baseline LDL-C levels $160 mg/dL
(4.1 mmol/L) and LONG TERM enrolled patients with
baseline LDL-C levels $70 mg/dL (1.8 mmol/L).
In the FH I, FH II, COMBO I, and COMBO II studies, the
starting dose of alirocumabwas 75mgQ2W.A dose increasen this analysis (randomized and treated population). Clinicaltrials.gov
); NCT01623115 (FH I); NCT01709500 (FH II); NCT01644175
creased from 75 mg Q2W to 150 mg Q2W at Week 12 depending
ular; FH, familial hypercholesterolemia; HeFH, heterozygous familial
pid-lowering therapy; Q2W, every 2 weeks.
Farnier et al Adherence to alirocumab in clinical trials 989to 150 mg Q2Woccurred at Week 12 if, at Week 8, patients
had LDL-C levels $70 mg/dL (1.8 mmol/L). Patients in
LONG TERM and HIGH FH received alirocumab 150 mg
Q2W throughout the study. Alirocumab was administered
subcutaneously using a 1mL prefilled pen, except for LONG
TERM, which used a prefilled syringe. Patients either self-
injected alirocumab or designated another person to assist
them with the injections, if desired. Self-injection training
using placebo was performed during the screening period.
Those in the control groups received placebo injections
subcutaneously to match the alirocumab Q2W injection
schedule. In COMBO II, ezetimibe was given orally, at a
daily dose of 10 mg, with or without food; patients in the
alirocumab arm received oral placebo for ezetimibe to
maintain the blinded nature of the trial.
The studies were performed in accordance with the
ethical principles in the Declaration of Helsinki, the
International Conference on Harmonization/Good Clinical
Practice, and appropriate local or regulatory requirements.
Informed consent was obtained from all patients included
in these studies.
Endpoints
Treatment adherence
Patient adherence to treatment with alirocumab or
control agents was based on information recorded by the
patient in a specified patient diary. For each injection
received, patients were required to record the date and
time of the injection and treatment kit number. These data
were then entered into electronic case report forms
(eCRFs) at the study sites; the study monitor cross-
checked the consistency between information recorded in
the eCRFs against that recorded in patient diaries and
against the number of returned unused syringes of a
corresponding kit.
Adherence to injections was reported as the percentage of
days that patients received injections according to the dosing
schedule. Patients’ adherence levels to injections were
divided into 4 categories: 100% adherent, those with
below-planned dosing, those with above-planned dosing,
and those with both below- and above-planned dosing. In the
case of below-planned dosing, this was defined as the number
of days with no injection administered within the previous
17 days divided by the duration of treatment-injection
exposure in days. For above-planned dosing, this was defined
as the number of days with.1 injection administered within
the previous 11 days divided by the duration of treatment-
injection exposure in days. Overall adherencewas calculated
for each patient as 100 2 (percentage of days with below-
planned dosing 1 percentage of days with above-planned
dosing). Evaluations of injection adherence levels took into
account the fact that injections were given Q2W6 3 days, as
defined in the study protocols.
Adherence to ezetimibe and placebo capsules in the
ezetimibe-controlled COMBO II trial was also based oninformation documented in patient dosing diaries. Infor-
mation from these diaries, including capsule kit number,
was logged into the eCRFs at study sites and cross-checked
against the returned kits. Adherence to capsules was
measured as the number of capsules taken multiplied by
100 divided by (the last capsule intake date 2 the first
capsule intake date 1 1). Good adherence to capsules was
defined as having taken $80% of capsules at the scheduled
time; poor adherence to capsules was defined as having
taken ,80% of capsules at the scheduled time.
LDL-C measurements
In the present analysis, the effect of alirocumab on LDL-C
level was evaluated by calculating the percentage change
from baseline to Week 52 in calculated LDL-C. Blood
samples were collected in the morning after a 10-hour
overnight fast and before administration of the study drug.
LDL-C concentrations were calculated using the Friedewald
formula.
Safety assessments
Safety was monitored continuously throughout the 6
studies. Treatment-emergent adverse events (TEAEs) were
defined as adverse events, which, irrespective of relation-
ship to study drug, developed, worsened, or became serious
during the period from the first to the last dose of study
treatment plus 70 days. In COMBO II, the first treatment
administration of the investigative medicinal product was
either a capsule or an injection, whichever came first.
Statistical considerations
Adherence and safety data were analyzed using the
safety population (randomized and treated) and were sum-
marized using descriptive statistics. The percentage change
from baseline to Week 52 in calculated LDL-C was
analyzed using the modified intent-to-treat population,
defined as all randomized patients who took at least 1 or
part of a dose of the study drug and had an evaluable
primary efficacy endpoint during the efficacy treatment
period (on-treatment approach). Missing data at Week 52
were imputed using the last value on-treatment.Results
Patient disposition and baseline characteristics
Across the 6 studies, 4212 patients were randomized and
treated: 2797 in the alirocumab arms and 1415 in the
control arms. Two pools were considered based on the
control arms in the trials: the placebo-controlled pool and
the ezetimibe-controlled pool (Fig. 1). Pooled baseline
characteristics are shown in Table 1. Mean age ranged
from 58.6 to 61.7 years and mean body mass index was
Table 1 Baseline patient characteristics (randomized and treated population)—placebo- and ezetimibe-controlled pools
Characteristic
Placebo-controlled trials Ezetimibe-controlled trial
Alirocumab (n 5 2318) Placebo (n 5 1174) Alirocumab (n 5 479) Ezetimibe (n 5 241)
Mean age (SD), y 58.6 (11.6) 58.8 (11.3) 61.7 (9.4) 61.3 (9.2)
Males, n (%) 1413 (61.0) 711 (60.6) 360 (75.2) 170 (70.5)
Race, White, n (%) 2136 (92.1) 1071 (91.2) 404 (84.3) 206 (85.5)
Mean BMI (SD), kg/m2 30.1 (5.6) 30.4 (5.6) 30.0 (5.4) 30.3 (5.1)
HeFH, n (%) 837 (36.1) 418 (35.6) 0 0
Diabetes, n (%) 698 (30.1) 356 (30.3) 148 (30.9) 77 (32.0)
ASCVD, n (%) 1611 (69.5) 834 (71.0) 461 (96.2) 224 (92.9)
ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; HeFH, heterozygous familial hypercholesterolemia; SD, standard deviation.
Pooled data from the 6 phase III ODYSSEY trials (FH I, FH II, HIGH FH, COMBO I, COMBO II, and LONG TERM) are shown.
990 Journal of Clinical Lipidology, Vol 11, No 4, August 201730.0 to 30.4 kg/m2. The proportion of patients with HeFH
was comparable among patients receiving alirocumab and
those receiving placebo. There were no patients with
HeFH recruited in COMBO II, which formed the
ezetimibe-controlled pool (Table 1). The proportion of pa-
tients with diabetes at baseline was similar between
alirocumab and control groups, ranging from 30.1% to
32.0%. Almost all (.92%) patients in the COMBO II trial
had atherosclerotic CVD, compared with 69.5% and 71%
in alirocumab and placebo arms, respectively, in pooled
placebo-controlled studies.
Adherence
Treatment adherence data were available for 4197 of
the 4212 patients, of whom 2786 received alirocumab
injections and 1411 received placebo injections. Treat-
ment adherence was high, with a mean overall adherence
of 98.0% in the alirocumab arm and 97.8% in the control
arm (Table 2). Within individual studies, overall mean
treatment adherence ranged from 97.6% to 98.3% among
the alirocumab arms and from 96.9% to 99.1% in control
arms (Fig. 2). Almost half of patients receiving
alirocumab (45.7%) or control (44.5%) were 100%Table 2 Overall treatment adherence to alirocumab or placebo inje
compliance), calculated as 100 2 (percentage of days with below-pla
Adherence parameter Al
Mean (SD) overall treatment adherence, % 9
Median overall treatment adherence, % 99
Min–max, % 44
Categories of treatment adherence, n (%)
100% adherence 12
Only below-planned dosing 5
Only above-planned dosing
Both below- and above-planned dosing 8
SD, standard deviation.
Pooled data from the 6 phase III ODYSSEY trials (FH I, FH II, HIGH FH, COadherent to their treatment regimen (Table 2). A compara-
ble proportion of patients in the alirocumab and control
groups experienced below-planned dosing only (20.4%
vs 23.0%), above-planned dosing only (2.9% vs 3.3%),
and both below- and above-planned dosing (31.1% vs
29.3%; Table 2). Adherence to ezetimibe or placebo
capsules (COMBO II study only) was also high, with a
mean of 96.8% in the alirocumab group and 97.6% in
the ezetimibe group (Table 3).
To determine whether adherence to alirocumab or
placebo injections were driven by variations in patient
characteristics, baseline characteristics were evaluated ac-
cording to the 4 treatment adherence categories. In all 4
categories, baseline characteristics were comparable be-
tween alirocumab and control groups (Table 4). Mean base-
line LDL-C values varied from 119.7 mg/dL (3.1 mmol/L)
to 132.5 mg/dL (3.43 mmol/L) in the different groups.
Effect on LDL-C
The percentage change from baseline to Week 52 in
calculated LDL-C in alirocumab-treated patients only
(ie, excluding the control arms) was evaluated according to
the 4 treatment adherence categories and alirocumab initialctions (randomized and treated population with evaluable
nned dosing 1 percentage of days with above-planned dosing)
irocumab, n 5 2786 Control, n 5 1411
8.0 (4.4) 97.8 (4.9)
.6 99.6
–100 46–100
72 (45.7) 628 (44.5)
67 (20.4) 324 (23.0)
81 (2.9) 46 (3.3)
66 (31.1) 413 (29.3)
MBO I, COMBO II, and LONG TERM) are shown.
Figure 2 Mean (SD) overall treatment adherence† (to alirocumab or placebo injections) in individual studies (randomized and treated
population). Clinicaltrials.gov identifiers: NCT01507831 (LONG TERM); NCT01617655 (HIGH FH); NCT01623115 (FH I);
NCT01709500 (FH II); NCT01644175 (COMBO I); NCT01644188 (COMBO II). †Overall treatment adherence was calculated as 100
2 (percentage of days with below-planned dosing 1 percentage of days with above-planned dosing). SD, standard deviation.
Farnier et al Adherence to alirocumab in clinical trials 991dose, using an on-treatment approach (on-treatment LDL-C
values). A total of 2738 patients in the alirocumab arm had
data for LDL-C during the on-treatment period. The mean
percentage change from baseline to Week 52 in calculated
LDL-C ranged from 245.8% to 261.9% and was broadly
comparable across all 4 treatment adherence categories
(Fig. 3). A total of 1148 patients were initiated on
alirocumab 75 mg Q2W, whereas 1590 patients were initi-
ated on alirocumab 150 mg Q2W (LONG TERM and
HIGH FH). Of those initiated on 75 mg alirocumab Q2W,
25.1% to 30.6% received dose increase to 150 mg
alirocumab Q2W at Week 12 (Fig. 3). For each adherence
category, the mean percentage reduction in calculated
LDL-C was slightly greater for those receiving alirocumab
150 mg Q2W vs those starting on 75 mg Q2W (with possible
increase to 150 mg Q2W; Fig. 3).Table 3 Overall treatment adherence to ezetimibe or placebo capsule
evaluable compliance), calculated as 100 ! the number of capsules t
Adherence parameter Placeb
Number of patients with available data 472
Mean (SD) overall treatment adherence, % 96.8 (
Median overall treatment adherence, % 99.6
Min–max, % 1–135
Categories of treatment adherence, n (%)
Poor adherence (patients with ,80% adherence) 18 (
Good adherence (patients with $80% adherence) 454 (
SD, standard deviation.
Data from the ezetimibe-controlled COMBO II study is shown.Safety analyses
All 4212 patients were included in the safety analysis.
Pooled safety data from the 6 studies are shown in Tables 5–7.
The rates of TEAEs, treatment-emergent serious adverse
events, and TEAEs leading to discontinuations or deaths
were generally comparable between alirocumab and control
arms (Table 5). The most common TEAE leading to treatment
discontinuation in the alirocumab group was myalgia, occur-
ring in 6 (0.3%) and 3 (0.6%) patients in the placebo- and
ezetimibe-controlled pools, respectively (Table 6). Within the
control groups, myalgia was also the most common TEAE
leading to discontinuation in the ezetimibe group (2 patients
[0.8%]); whereas back painwas themost commonTEAE lead-
ing to treatment discontinuation in the placebo group (4 pa-
tients [0.3%]). There were no cases of myalgia leading tos in the COMBO II study (randomized and treated population with
aken/(last capsule intake date 2 first capsule intake date 1 1)
o capsule for ezetimibe, n 5 479 Ezetimibe, n 5 241
237
8.7) 97.6 (5.7)
99.4
47–115
3.8) 4 (1.7)
96.2) 233 (98.3)
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992 Journal of Clinical Lipidology, Vol 11, No 4, August 2017treatment discontinuation in the placebo group (Table 6). Injec-
tion site reactions led to treatment discontinuation in a small
number of patients: 4 (0.2%; placebo-controlled pool) and 2
(0.4%; ezetimibe-controlled pool) patients in the alirocumab
group vs 3 patients (0.3%) in the placebo group and 1 (0.4%)
in the ezetimibe group (Table 6). The rates of TEAEs were
also similar among the different treatment adherence cate-
gories, ranging from 77.9% (100% adherence) to 84.7%
(below-planned dosing) in alirocumab arms and 73.9%
(above-planned dosing) to 84.9% (below-planned dosing) in
control arms (Table 7). In the 100% adherence group, 9.7%
of patients receiving alirocumab discontinued treatment due
to TEAEs, compared with 8.6% in the above-planned dosing
group, 5.5% in the below-planned dosing group, and 2.9% in
the both above- and below-planned dosing group (Table 7).
The proportion of TEAEs leading to treatment discontinuation
was comparable between alirocumab and control groups for
patients in the 100% adherence group (9.7% vs 8.3%, respec-
tively) and those with below-planned dosing (5.5% vs 4.6%,
respectively; Table 7).
Discussion
Injectable biologics and medications are becoming
increasingly common in the primary care setting, beyond
their use in diabetes management, for the treatment of
chronic illnesses.32,33 Although they represent an important
step in the management of chronic diseases, the high cost of
biologics and diverse administration methods may nega-
tively impact treatment adherence.33 As therapeutic out-
comes are linked to adequate treatment adherence,
understanding adherence to biologics over the long term
is therefore important to ensuring optimal outcomes for
patients.32
In the CV setting, it is widely accepted that global
adherence to oral CV medications is generally suboptimal
and that this has an adverse influence on patient out-
comes.10,14 In a meta-analysis based on incidence rates in
the European Union population, the relative risks of devel-
oping CVD in patients with good ($80%) vs bad (,80%)
adherence were 0.85 for statins and 0.81 for antihyperten-
sive medications.14 The relative risks of all-cause mortality
were 0.55 and 0.71 for good adherence to statins and anti-
hypertensive agents.14 It is therefore reasonable to infer that
a considerable proportion of CVD events may be caused by
suboptimal adherence to oral CV therapies. As injectable
biologics penetrate the CV field, adherence to such agents,
in addition to their proven efficacy, is likely to play a
pivotal role in determining whether CV outcomes can be
enhanced.
In this analysis from 6 Phase III ODYSSEY trials,
adherence to treatment with subcutaneous, injectable
alirocumab or placebo over a period of $1 year was
high, with an overall adherence rate of w98% in both
alirocumab and control groups. Within individual studies,
adherence rates ranged from 97.6% to 98.3% among the
alirocumab treatment groups. Adherence rates for control
Figure 3 Alirocumab-induced percentage change in LDL-C from baseline to Week 52 according to treatment adherence category and
starting dose regimen (modified ITT population). Pooled data from patients treated in the alirocumab arm of 6 phase III ODYSSEY trials
(FH I, FH II, HIGH FH, COMBO I, COMBO II, and LONG TERM) are shown. Patients received alirocumab 150 mg Q2W in LONG
TERM and HIGH FH studies, whereas patients in the remaining studies received an initial alirocumab dose of 75 mg Q2W with the pos-
sibility of dose increase to 150 mg Q2W at week 12 based on LDL-C at Week 8. Boxplots were based on calculated LDL-C values during
the on-treatment period (modified ITT population). Missing data at Week 52 imputed using last value on-treatment. The central line within
a given box represents the median, and the mean is denoted by the diamond. The lower and upper boundaries of the box represent the lower
(Q1) and upper (Q3) quartiles. The ends of the ‘‘whiskers’’ signify Q12 1.5 interquartile range and Q31 1.5 interquartile range. The small
circles above each box denote the outliers (.Q3 1 1.5 interquartile range). †Patients received an initial dose of 75 mg Q2W alirocumab,
which was increased in an automated manner to 150 mg Q2W at Week 12 depending on LDL-C levels at Week 8. N: number of patients
with adherence nonmissing and at least 1 nonmissing LDL-C value during the on-treatment period. ITT, intent-to-treat; LDL-C, low-density
lipoprotein cholesterol; Q2W, every 2 weeks; SD, standard deviation.
Farnier et al Adherence to alirocumab in clinical trials 993were similar, ranging from 96.9% to 99.1%. Treatment
adherence to oral ezetimibe and placebo capsules (COMBO
II study) was also high, with 98.3% and 96.2% of patients,
respectively, having adherence rates of at least 80%.
Adherence to therapy may be influenced by patient-
related factors.34 In the context of hypercholesterolemia, pa-
tients who have previously experienced a CVevent might be
expected to be more adherent to alirocumab than those who
have not. Similarly, patients with diabetes, who may be
familiar with injectable medications, or those with HeFH,
who have a heightened awareness of their disease and the
implications of treatment, could be expected to be more
adherent than the overall population. In the
present analysis, baseline characteristics were generally
comparable among patients who had 100% adherence,below-planned dosing only, above-planned dosing only,
and both below- and above-planned dosing. Although pa-
tients with diabetes, HeFH, or atherosclerotic CVD were
well represented in this analysis, the proportion of patients
with these indications was generally similar between the
100% adherent group and the above- and/or below-
planned dosing groups. Very few patients had above-
planned dosing. Further assessment of the impact of
patient-related factors on treatment adherence, for example
by comparing adherence in patients with HeFH or diabetes
vs those without these conditions in a real-world setting,
is required to fully understand whether adherence to
alirocumab differs among patient subgroups.
Practical considerations with respect to injectable bi-
ologics, such as willingness to self-inject or availability of a
Table 5 Overall safety summary (randomized and treated
population)—global pool
n (%)
Alirocumab
(n 5 2797)
Control
(n 5 1415)
TEAEs 2242 (80.2) 1152 (81.4)
Treatment-emergent SAEs 509 (18.2) 262 (18.5)
TEAEs leading to death 22 (0.8) 19 (1.3)
TEAEs leading to treatment
discontinuation
188 (6.7) 86 (6.1)
SAE, serious adverse event; TEAE, treatment-emergent adverse
event.
Pooled data from the 6 phase III ODYSSEY trials (FH I, FH II, HIGH FH,
COMBO I, COMBO II, and LONG TERM).
994 Journal of Clinical Lipidology, Vol 11, No 4, August 2017caregiver, may also influence adherence rates.35 For
example, adherence to self-injections appears to be greater
than injection by a caregiver or healthcare professional,
and subcutaneous injections with auto-injectors or pen
devices are generally favored over needle and syringe admin-
istration.32,36 Dosing schedules also play an important role in
treatment adherence. It has been suggested that prolonged in-
tervals between doses, such as Q2Wdosing with alirocumab,
may minimize the burden on patients and enhance adher-
ence.35 Another PCSK9 inhibitor, evolocumab, is approved
with both Q2W and once-monthly dosing schedules,24 and
clinical trial data suggest that alirocumab may also be dosed
on a monthly basis.37,38 However, whether monthly adminis-
tration of either alirocumab or evolocumab translates into
improved adherence vs Q2W administration over the long
term remains to be seen.
A key limitation of this analysis is that it was based on
randomized controlled trials, which are typically associated
with high levels of treatment adherence.2 The findings pre-
sented here may therefore not accurately reflect alirocumab
adherence patterns in everyday clinical practice. Indeed,
adherence to statins reported in clinical trials is greater
than that observed in real-world settings (78%–90% vsTable 6 TEAEs leading to treatment discontinuation in $0.4% of a
population)—placebo- and ezetimibe-controlled pools
n (%)
Placebo-controlled pool
Alirocumab (n 5 2318) Placebo (n
Myalgia 6 (0.3) 0
Dizziness 2 (,0.1) 3 (0.3)
Ischemic stroke* 2 (,0.1) 0
Vision blurred 1 (,0.1) 0
Diarrhea 3 (0.1) 1 (,0.1)
Back pain 1 (,0.1) 4 (0.3)
Renal cyst 0 1 (,0.1)
Injection site reaction 4 (0.2) 3 (0.3)
Increased transaminases 1 (,0.1) 0
TEAE, treatment-emergent adverse event.
Pooled data from the 6 phase III ODYSSEY trials (FH I, FH II, HIGH FH, CO
*Only 1 event in the ezetimibe-controlled pool was considered related to s44%–57%, respectively).11,12 In the Collaborative Atorvas-
tatin Diabetes Study, in which patients with type II diabetes
but no history of CVD were randomized to receive atorvas-
tatin or placebo, 90% of patients allocated to the atorvasta-
tin group were taking atorvastatin (and/or another statin)
after 1 year, and 87% were taking atorvastatin (and/or
another statin) at 2 years (85% of patients on average
were taking atorvastatin and/or another statin over a 4-
year period).12 In a cluster randomized sub-study of the
Atorvastatin in Factorial with Omega EE90 Risk Reduction
in Diabetes trial, adherence to atorvastatin over 1 year was
w79%.13 An average statin adherence rate of 85% was also
demonstrated over a 5-year period in patients with diabetes
from the large, randomized controlled Heart Protection
Study.11 In contrast, based on data from the Finnish FinDM
database, the average adherence rate to statins over
w3 years in patients with type II diabetes in the real-
world setting was reported to be 57%.11 Similarly, in a
retrospective cohort study using the Saskatchewan Drug
Plan and Extended Benefits database in Canada, adherence
to statins was 52% in the first year and 44% by the third
year.39 Real-world data on adherence to ezetimibe capsules
are limited; however, 1 retrospective study investigating
oral LLTs, including the combination of ezetimibe and sim-
vastatin, in a managed care setting demonstrated that mean
proportion of days covered fell below the threshold for
adherence (80%) even within the first 3 months of ther-
apy.40 This contrasts with the .80% to 97% adherence
rates observed with ezetimibe plus statin therapy at within
the first 3 months of treatment in clinical trials.41,42 The
introduction of injectable agents for asymptomatic condi-
tions, such as hypercholesterolemia, has been met with un-
certainties regarding patients’ willingness to self-inject and
maintain the injection schedule over the long term
compared with taking oral drugs on a daily basis. Results
from this and a previous study27 suggest that acceptance
of and adherence to injectable alirocumab is high in clinical
trials. However, they also raise the question of howlirocumab-treated patients in any pool (randomized and treated
Ezetimibe-controlled pool
5 1174) Alirocumab (n 5 479) Ezetimibe (n 5 241)
3 (0.6) 2 (0.8)
2 (0.4) 1 (0.4)
2 (0.4) 0
2 (0.4) 0
2 (0.4) 0
2 (0.4) 1 (0.4)
2 (0.4) 0
2 (0.4) 1 (0.4)
2 (0.4) 0
MBO I, COMBO II, and LONG TERM).
tudy treatment.
Ta
b
le
7
O
ve
ra
ll
TE
A
Es
an
d
TE
A
Es
le
ad
in
g
to
tr
ea
tm
en
t
d
is
co
n
ti
n
u
at
io
n
in
al
ir
o
cu
m
ab
-t
re
at
ed
p
at
ie
n
ts
,
ac
co
rd
in
g
to
tr
ea
tm
en
t
ad
h
er
en
ce
ca
te
g
o
ri
es
(r
an
d
o
m
iz
ed
an
d
tr
ea
te
d
p
o
p
u
la
ti
o
n
)
n
(%
)
1
0
0
%
ad
h
er
en
ce
B
el
o
w
-p
la
n
n
ed
d
o
si
n
g
A
b
o
ve
-p
la
n
n
ed
d
o
si
n
g
B
o
th
b
el
o
w
-
an
d
ab
o
ve
-p
la
n
n
ed
d
o
si
n
g
A
li
ro
cu
m
ab
(n
5
1
2
7
2
)
Co
n
tr
o
l
(n
5
6
2
8
)
A
li
ro
cu
m
ab
(n
5
5
6
7
)
Co
n
tr
o
l
(n
5
3
2
4
)
A
li
ro
cu
m
ab
(n
5
8
1
)
Co
n
tr
o
l
(n
5
4
6
)
A
li
ro
cu
m
ab
(n
5
8
6
6
)
Co
n
tr
o
l
(n
5
4
1
3
)
TE
A
Es
9
9
1
(7
7
.9
)
4
9
4
(7
8
.7
)
4
8
0
(8
4
.7
)
2
7
5
(8
4
.9
)
6
8
(8
4
.0
)
3
4
(7
3
.9
)
6
9
7
(8
0
.5
)
3
4
5
(8
3
.5
)
Tr
ea
tm
en
t-
em
er
g
en
t
SA
Es
2
0
5
(1
6
.1
)
9
7
(1
5
.4
)
1
1
9
(2
1
.0
)
7
9
(2
4
.4
)
1
2
(1
4
.8
)
7
(1
5
.2
)
1
7
0
(1
9
.6
)
7
8
(1
8
.9
)
TE
A
Es
le
ad
in
g
to
d
ea
th
1
1
(0
.9
)
1
0
(1
.6
)
4
(0
.7
)
5
(1
.5
)
0
0
5
(0
.6
)
3
(0
.7
)
TE
A
Es
le
ad
in
g
to
d
is
co
n
ti
n
u
at
io
n
1
2
3
(9
.7
)
5
2
(8
.3
)
3
1
(5
.5
)
1
5
(4
.6
)
7
(8
.6
)
1
(2
.2
)
2
5
(2
.9
)
1
8
(4
.4
)
SA
E,
se
ri
o
u
s
ad
ve
rs
e
ev
en
t;
TE
A
E,
tr
ea
tm
en
t-
em
er
g
en
t
ad
ve
rs
e
ev
en
t.
P
o
o
le
d
d
at
a
fr
om
th
e
6
p
h
as
e
II
I
O
D
YS
SE
Y
tr
ia
ls
(F
H
I,
FH
II
,
H
IG
H
FH
,
CO
M
B
O
I,
CO
M
B
O
II
,
an
d
LO
N
G
TE
R
M
).
Farnier et al Adherence to alirocumab in clinical trials 995adherence to a therapy requiring Q2W injections (26 injec-
tions per year) and adequate refrigeration compares with
that of an oral drug that is given daily (365 administrations
per year) and does not require refrigeration in the real-
world setting.
Open-label extension studies, such as ODYSSEY OLE
(NCT01954394), are ongoing. In these studies, patients will
have the opportunity to observe the impact of their
treatment, which may consequently impact adherence
levels. The results of these studies may therefore provide
further insight into long-term adherence to alirocumab in a
setting that is closer to clinical practice than randomized
controlled trials. In addition, although treatment adherence
was high over a period of 1 to 2 years in a relatively large
patient population in this analysis, it remains to be seen
whether treatment adherence levels remain high over a
period of follow-up longer than 2 years and in larger patient
populations. Adherence to alirocumab injections will be
further assessed in a large, ongoing CV outcomes study
(ODYSSEY OUTCOMES) of approximately 18,000 pa-
tients randomized to either alirocumab or placebo with a
planned follow-up period of $2 years.43
Mean percentage changes from baseline to Week 52 in
LDL-C were not markedly different in patients who had
100% adherence, below-planned dosing only, above-
planned dosing only, or both below- and above-planned
dosing. As the endpoint in the studies included in this
analysis was mean percentage change in LDL-C over time,
individual changes in LDL-C levels calculated at a given
patient visit are not represented here. Although the impact
of above- or below-planned dosing of alirocumab on
LDL-C levels at specific patient visits is currently un-
known, the average percentage change in LDL-C was not
significantly affected by above- or below-planned dosing.
The average of LDL-C levels taken over several visits
might provide a more balanced view of a patient’s LDL-C
levels in response to treatment than a single measurement
taken at 1 visit, which could result in unnecessary dose
adjustment. Deviations greater than 63 days from the
dosing frequency of Q2W did not meaningfully affect the
percentage of LDL-C reduction. For injectable medica-
tions, TEAEs are often highlighted as a reason for poor
adherence and treatment discontinuation.32,44,45 In this
analysis, alirocumab was generally well tolerated and had
a favorable safety profile, with few TEAEs leading to treat-
ment discontinuation. Injection site reactions, which can be
frequently observed with injectable medications, were
generally mild in severity and led to treatment discontinu-
ations in ,1% of the study population.Conclusions
In conclusion, the results presented here indicate that, in
clinical trials, alirocumab injections, via self-injection or
with the help of a caregiver, are associated with a high level
of adherence over a period of at least 1 year, and that
996 Journal of Clinical Lipidology, Vol 11, No 4, August 2017infrequent below- or above-planned dosing had minimal
impact on LDL-C reductions. This further supports the use
of alirocumab 75 mg Q2W (with possible adjustment to
150 mg Q2W) and 150 mg Q2W over the long term to
achieve clinically meaningful LDL-C reductions in patients
with HeFH or high CV risk.
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